外用多塞平引起的变应性接触性皮炎：美国食品药品监督管理局的上市后监测经验。

Allergic contact dermatitis from topical doxepin: Food and Drug Administration's postmarketing surveillance experience.

作者信息

Bonnel Renan A, La Grenade Lois, Karwoski Claudia B, Beitz Julie G

机构信息

Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Room 15B-23, HFD-430, Rockville, MD 20857, USA.

出版信息

J Am Acad Dermatol. 2003 Feb;48(2):294-6. doi: 10.1067/mjd.2003.46.

DOI:10.1067/mjd.2003.46

PMID:12582408

Abstract

A total of 26 postmarketing cases of allergic contact dermatitis to doxepin 5% cream were reported to the Food and Drug Administration. Our findings suggest that allergic contact dermatitis was more common when treatment duration exceeded the recommended 8 days. Allergic contact dermatitis to doxepin cream should be considered in patients whose condition fails to improve or worsens with doxepin use.

摘要

共有26例使用5%多塞平乳膏后发生过敏性接触性皮炎的上市后病例报告给了美国食品药品监督管理局。我们的研究结果表明，当治疗持续时间超过推荐的8天时，过敏性接触性皮炎更为常见。对于使用多塞平后病情未改善或恶化的患者，应考虑多塞平乳膏引起的过敏性接触性皮炎。